View Document Preview and Link Document Date: 2015-03-08 19:04:08 Open Document File Size: 110,65 KB Share Result on Facebook
City NORTHBROOK / / Company Basilea Pharmaceutica International Ltd. / Astellas / Facebook / Twitter / / Currency CHF / / / Event FDA Phase / / Facility The University of Texas Health Science Center / / IndustryTerm pharmaceutical / food / pharmaceuticals / / MedicalCondition headache / Stevens Johnson syndrome / zygomycosis / convulsion / severe hepatic injury / nausea / anaphylaxis / Invasive Aspergillosis Invasive aspergillosis / Invasive Mucormycosis Invasive mucormycosis / hypoesthesia / mucormycosis / hypersensitivity / diarrhea / hepatitis / constipation / confusional state / liver disease / infections / back pain / Invasive Mucormycosis NORTHBROOK / fungal infections / hypotension / Invasive Aspergillosis / leukemia / invasive mucormycosis / respiratory failure / invasive mucormycosis fungal infections / dyspnea / chills / Serious hypersensitivity / vomiting / familial short QT syndrome / invasive fungal disease / hepatic failure / infectious diseases / epilepsy / fungal infection / invasive fungal infections / dizziness / cough / hypokalemia / Infectious Disease / paresthesia / cholestasis / acute renal failure / invasive fungal infection / hematologic malignancy / / Organization Division of Infectious Diseases / U.S. Food and Drug Administration / FDA / San Antonio Center for Medical Mycology / University of Texas Health Science Center at San Antonio / / Person Stevens Johnson / Bernie Zeiher / Thomas F. Patterson / / / Position physician / chief / director / executive vice president / vice president / Global Development and therapeutic area head / / Product carbamazepine / rifampin / ketoconazole / CRESEMBA® (isavuconazonium sulfate) / / ProvinceOrState Illinois / / PublishedMedium Medical Mycology / / URL www.astellas.us / www.twitter.com/AstellasUS / www.facebook.com/?ref=tn_tnmn#!/AstellasUS / / SocialTag 
NEWS RELEASE Contact: Marjorie Moeling [removed[removed]Astellas Receives FDA Approval for CRESEMBA® (isavuconazonium sulfate)